Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide

Pharmacotherapy

Volumn 34, Issue 11, 2014, Pages 1132-1140

  Moore, Mariellen J ^a   Gong, Yan ^a   Hou, Wei ^b   Hall, Karen ^c   Schmidt, Siegfried O F ^c   Curry, Robert Whitney ^c   Beitelshees, Amber L ^d   Chapman, Arlene ^e   Turner, Stephen T ^f   Schwartz, Gary L ^f   Bailey, Kent ^f   Boerwinkle, Eric ^g   Gums, John G ^a,c   Cooper Dehoff, Rhonda M ^a,c   Johnson, Julie A ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Mayo Clinic College of Medicine   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

atenolol; hydrochlorothiazide; hyperglycemia; impaired fasting glucose; thiazide diuretics; Blockers

Indexed keywords

ATENOLOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN; POTASSIUM; URIC ACID; ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; GLUCOSE BLOOD LEVEL;

ADD ON THERAPY; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; BLACK PERSON; BLOOD PRESSURE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; WAIST CIRCUMFERENCE; ADVERSE EFFECTS; ANALYSIS; BIOLOGICAL MODEL; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; MIDDLE AGED; RISK; UNITED STATES; VALIDATION STUDY;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD GLUCOSE; COHORT STUDIES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERGLYCEMIA; HYPERTENSION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RISK; ROC CURVE; UNITED STATES;

EID: 84908886185     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1483     Document Type: Article

References (37)

1. Elliott WJ, Meyer PM,. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-7.
2. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
3. Cooper-Dehoff R, Cohen JD, Bakris GL, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006; 98: 890-4.
4. Bangalore S, Parkar S, Grossman E, Messerli FH,. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100: 1254-62.
5. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
6. Stump CS, Hamilton MT, Sowers JR,. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006; 81: 796-806.
7. Carter BL, Einhorn PT, Brands M, et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension 2008; 52: 30-6.
8. Cooper-DeHoff RM,. Thiazide-induced dysglycemia: it's time to take notice. Expert Rev Cardiovasc Ther 2008; 6: 1291-4.
9. Chrysant SG, Chrysant GS, Dimas B,. Current and future status of beta-blockers in the treatment of hypertension. Clin Cardiol 2008; 31: 249-52.
10. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-9.
11. Cooper-DeHoff RM, Wen S, Beitelshees AL, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2010; 55: 61-8.
12. Maitland-van dZA, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E,. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens 2005; 18: 1077-83.
13. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK,. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007; 25: 1311-7.
14. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S,. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007; 50: 467-73.
15. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H,. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ 2003; 326: 681.
16. Johnson JA, Boerwinkle E, Zineh I, et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009; 157: 442-9.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
18. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Sepe A, Tchkonia T, Thomou T, Zamboni M, Kirkland JL,. Aging and regional differences in fat cell progenitors-a mini-review. Gerontology 2011; 57: 66-75.
20. Poledne R, Lorenzova A, Stavek P, et al. Proinflammatory status, genetics and atherosclerosis. Physiol Res 2009; 58 (Suppl 2): S111-8.
21. Boden G, Shulman GI,. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32 (Suppl 3): 14-23.
22. Lewis GF, Carpentier A, Adeli K, Giacca A,. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-29.
23. Bjorntorp P,. Metabolic implications of body fat distribution. Diabetes Care 1991; 14: 1132-43.
24. Berg AH, Scherer PE,. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-49.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
26. Schneider HJ, Friedrich N, Klotsche J, et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab 2010; 95: 1777-85.
27. Ghandehari H, Le V, Kamal-Bahl S, Bassin SL, Wong ND,. Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int J Obes (Lond) 2009; 33: 239-48.
28. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-9.
29. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S,. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005; 149: 54-60.
30. Leitzmann MF, Moore SC, Koster A, et al. Waist circumference as compared with body-mass index in predicting mortality from specific causes. PLoS ONE 2011; 6: e18582.
31. Testa G, Cacciatore F, Galizia G, et al. Waist circumference but not body mass index predicts long-term mortality in elderly subjects with chronic heart failure. J Am Geriatr Soc 2010; 58: 1433-40.
32. Nichols GA, Hillier TA, Brown JB,. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med 2008; 121: 519-24.
33. Tirosh A, Shai I, Tekes-Manova D, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353: 1454-62.
34. Yeboah J, Bertoni AG, Herrington DM, Post WS, Burke GL,. Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2011; 58: 140-6.
35. Cicero AF, Derosa G, Rosticci M, et al. Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: a 12-years follow-up of the Brisighella Heart Study historical cohort. Diabetes Res Clin Pract 2014; 104: 183-8.
36. Matsuda M, DeFronzo RA,. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-70.
37. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166: 2191-201.